PMID- 14511399
OWN - NLM
STAT- MEDLINE
DCOM- 20040430
LR  - 20240412
IS  - 1522-8002 (Print)
IS  - 1476-5586 (Electronic)
IS  - 1476-5586 (Linking)
VI  - 5
IP  - 4
DP  - 2003 Jul-Aug
TI  - The presence of anti-p53 antibodies in sera prior to thoracic surgery in non 
      small cell lung cancer patients: its implications on tumor volume, nodal 
      involvement, and survival.
PG  - 283-7
LID - S1476-5586(03)80021-0 [pii]
LID - 10.1016/S1476-5586(03)80021-0 [doi]
AB  - BACKGROUND: During recent years, a correlation between the presence of antibodies 
      in sera against p53 and survival has been reported. The aim of the present study 
      was to analyze anti-p53 antibodies in sera from patients with non small cell lung 
      cancer (NSCLC) prior to thoracic surgery and their correlation to survival, nodal 
      involvement, and tumor volume. PATIENTS AND METHODS: Serum samples from 58 
      patients with NSCLC admitted to the Department of Pulmonary Medicine in Uppsala 
      were collected between 1993 and 1995 and analyzed for the expression of anti-p53 
      antibodies. RESULTS: Antibodies against p53 were detected in 12 patients (21%). 
      No association was found between increased levels of anti-p53 antibodies and 
      tumor volume (P =.84). There was a numerical trend towards higher levels of 
      anti-p53 antibodies in patients without nodal disease, when compared with 
      patients with nodal involvement, although not statistically significant (P 
      =.136). However, when patients with metastatic disease were included, 
      statistically significantly lower levels of anti-p53 antibodies were 
      demonstrated, in comparison to patients without any sign of nodal engagement or 
      metastatic disease (P =.038). Anti-p53 antibodies and survival showed no 
      correlation between increasing index levels of anti-p53 antibodies and survival 
      (P =.18). Neither was a correlation found between using the cutoff (>1.1) 
      described by the manufacturer and survival. CONCLUSION: The presence of anti-p53 
      antibodies was correlated neither to survival nor to tumor volume in the present 
      study. However, patients with either nodal or metastatic disease had lower levels 
      of anti-p53 antibodies in comparison to patients without signs of either nodal or 
      metastatic disease. These issues are discussed.
FAU - Bergqvist, Michael
AU  - Bergqvist M
AD  - Section of Oncology, Department of Oncology, Radiology, Clinical Immunology, 
      Uppsala University Hospital, University of Uppsala, Uppsala, Sweden. 
      bergqvist@onkologi.uu.se
FAU - Brattstrom, Daniel
AU  - Brattstrom D
FAU - Lamberg, Kristina
AU  - Lamberg K
FAU - Hesselius, Patrik
AU  - Hesselius P
FAU - Wernlund, Johan
AU  - Wernlund J
FAU - Larsson, Anders
AU  - Larsson A
FAU - Wagenius, Gunnar
AU  - Wagenius G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Neoplasia
JT  - Neoplasia (New York, N.Y.)
JID - 100886622
RN  - 0 (Antibodies)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
MH  - Antibodies/*blood
MH  - Antibodies, Anti-Idiotypic/blood
MH  - Carcinoma, Non-Small-Cell Lung/*blood/immunology/mortality
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Humans
MH  - Lung Neoplasms/*blood/immunology/mortality
MH  - Neoplasm Metastasis
MH  - Prognosis
MH  - Thoracic Surgery
MH  - Time Factors
MH  - Tumor Suppressor Protein p53/*blood/*immunology
PMC - PMC1502415
EDAT- 2003/09/27 05:00
MHDA- 2004/05/01 05:00
PMCR- 2003/07/01
CRDT- 2003/09/27 05:00
PHST- 2003/09/27 05:00 [pubmed]
PHST- 2004/05/01 05:00 [medline]
PHST- 2003/09/27 05:00 [entrez]
PHST- 2003/07/01 00:00 [pmc-release]
AID - S1476-5586(03)80021-0 [pii]
AID - 03136 [pii]
AID - 10.1016/S1476-5586(03)80021-0 [doi]
PST - ppublish
SO  - Neoplasia. 2003 Jul-Aug;5(4):283-7. doi: 10.1016/S1476-5586(03)80021-0.